Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population.
Adaptive resistance is a major limitation in the use of targeted therapies for cancer. Using real time biomass tracking, we demonstrate the isolation and identification of rare (1% fraction) diffuse large B cell lymphoma cells resistant to the PI3K inhibitor idelalisib, from an otherwise sensitive population. This technique allows direct study of these rare, drug tolerant cells.
Published In/Presented At
Murray, G. F., , Guest, D., , Mikheykin, A., , Toor, A., , & Reed, J., (2021). Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population. The Analyst, 146(4), 1157–1162. https://doi.org/10.1039/d0an01769h
Medicine and Health Sciences
Department of Medicine, Hematology-Medical Oncology Division